Staff directory Enric Calucho Palma

Enric Calucho Palma

Doctoral Student
FPI SO 2018
enric.calucho(ELIMINAR)@icn2.cat
Nanobioelectronics and Biosensors

Publications

2021

  • Attomolar analyte sensing techniques (AttoSens): A review on a decade of progress on chemical and biosensing nanoplatforms

    Usha S.P., Manoharan H., Deshmukh R., Álvarez-Diduk R., Calucho E., Sai V.V.R., Merkoçi A. Chemical Society Reviews; 50 (23): 13012 - 13089. 2021. 10.1039/d1cs00137j. IF: 54.564

    Detecting the ultra-low abundance of analytes in real-life samples, such as biological fluids, water, soil, and food, requires the design and development of high-performance biosensing modalities. The breakthrough efforts from the scientific community have led to the realization of sensing technologies that measure the analyte's ultra-trace level, with relevant sensitivity, selectivity, response time, and sampling efficiency, referred to as Attomolar Analyte Sensing Techniques (AttoSens) in this review. In an AttoSens platform, 1 aM detection corresponds to the quantification of 60 target analyte molecules in 100 μL of sample volume. Herein, we review the approaches listed for various sensor probe design, and their sensing strategies that paved the way for the detection of attomolar (aM: 10-18 M) concentration of analytes. A summary of the technological advances made by the diverse AttoSens trends from the past decade is presented. This journal is © The Royal Society of Chemistry.


  • Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and beyond

    Rosati G., Idili A., Parolo C., Fuentes-Chust C., Calucho E., Hu L., Castro E Silva C.D.C., Rivas L., Nguyen E.P., Bergua J.F., Alvárez-Diduk R., Muñoz J., Junot C., Penon O., Monferrer D., Delamarche E., Merkoçi A. ACS Nano; 15 (11): 17137 - 17149. 2021. 10.1021/acsnano.1c06839. IF: 15.881

    The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice. ©


2020

  • Tutorial: design and fabrication of nanoparticle-based lateral-flow immunoassays

    Parolo C., Sena-Torralba A., Bergua J.F., Calucho E., Fuentes-Chust C., Hu L., Rivas L., Álvarez-Diduk R., Nguyen E.P., Cinti S., Quesada-González D., Merkoçi A. Nature Protocols; 15 (12): 3788 - 3816. 2020. 10.1038/s41596-020-0357-x. IF: 10.419

    Lateral-flow assays (LFAs) are quick, simple and cheap assays to analyze various samples at the point of care or in the field, making them one of the most widespread biosensors currently available. They have been successfully employed for the detection of a myriad of different targets (ranging from atoms up to whole cells) in all type of samples (including water, blood, foodstuff and environmental samples). Their operation relies on the capillary flow of the sample throughout a series of sequential pads, each with different functionalities aiming to generate a signal to indicate the absence/presence (and, in some cases, the concentration) of the analyte of interest. To have a user-friendly operation, their development requires the optimization of multiple, interconnected parameters that may overwhelm new developers. In this tutorial, we provide the readers with: (i) the basic knowledge to understand the principles governing an LFA and to take informed decisions during lateral flow strip design and fabrication, (ii) a roadmap for optimal LFA development independent of the specific application, (iii) a step-by-step example procedure for the assembly and operation of an LF strip for the detection of human IgG and (iv) an extensive troubleshooting section addressing the most frequent issues in designing, assembling and using LFAs. By changing only the receptors, the provided example procedure can easily be adapted for cost-efficient detection of a broad variety of targets. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.